Covid-19 roundup: US expects 'nice increase' in J&J vaccine supply — report; CureVac amends trial protocols for variant efficacy
Despite a slow-paced launch of Johnson & Johnson’s vaccine in the US, the pharma should come close to its 20 million-dose target by the end of the month, White House Covid-19 adviser Andy Slavitt told reporters on Monday, per Reuters.
Since landing a EUA late last month, the company has shipped about 4.25 million doses in total, and only 2.3 million have been administered in the US, Reuters reported. But Slavitt said the company isn’t too far behind on its promise, adding that the country should see a “nice increase” this week.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
